Mariska de Munnik

Mariska de Munnik

Auto-generated profile, based on publicly available information

Mariska de Munnik

Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute of Antimicrobial Research, University of Oxford

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2019 in ChemBioChem
Verified
Journal Article
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
CLChristopher T. Lohans
Christopher T. Lohans
GLGareth W. Langley
Gareth W. Langley
CBCorentin BON
Corentin BON
JBJurgen Brem
Jurgen Brem
CSChristopher J. Schofield
Christopher J. Schofield
Mycobacterium tuberculosis l,d‐transpeptidases (Ldts), which are involved in cell‐wall biosynthesis, have emerged as promising targets for the treatment of tuberculosis. However, an efficient method for testing inhibition of these enzymes is not currently available. We present a fluorescence‐based assay for LdtMt2, which is suitable for high‐throughput screening. Two fluorogenic probes were identified that release a fluorophore upon reaction with LdtMt2, thus making it possible to assess the availability of the catalytic site in the presence of inhibitors. The assay was applied to a panel of β‐lactam antibiotics and related inhibitors; the results validate observations that the (carba)penem subclass of β‐lactams are more potent Ldt inhibitors than other β‐lactam classes, though unexpected variations in potency were observed. The method will enable systematic structure–activity relationship studies on Ldts, thereby facilitating the identification of new antibiotics active against M. tuberculosis.

30 May 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
PLPauline Lang
Pauline Lang
FAFrancisco De Dios Anton
Francisco De Dios Anton
MCMónica Cacho
Mónica Cacho
RBRobert H. Bates
Robert H. Bates
CSChristopher J. Schofield
Christopher J. Schofield
10 000 electrophilic compounds were screened for inhibition of the essential l,d -transpeptidase (Ldt Mt2 ) of Mycobacterium tuberculosis . Potent covalently reacting inhibitors were identified and characterised by protein X-ray and MS studies.

2 October 2023 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
JLJasper Lithgow
Jasper Lithgow
LBLennart Brewitz
Lennart Brewitz
KCKirsten E. Christensen
Kirsten E. Christensen
RBRobert H. Bates
Robert H. Bates
CSChristopher J. Schofield
Christopher J. Schofield
αβ,α′β′-Diepoxyketones (DEKs) inhibit nucleophilic cysteine enzymes. DEKs react with a transpeptidase and the SARS-CoV-2 main protease via epoxide opening; retro-aldol and other reactions can then occur, enabling irreversible alkylation.

18 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
PLPauline Lang
Pauline Lang
KCKarina Calvopiña
Karina Calvopiña
PRPatrick Rabe
Patrick Rabe
JBJurgen Brem
Jurgen Brem
CSChristopher J. Schofield
Christopher J. Schofield
The essential l,d-transpeptidase of Mycobacterium tuberculosis (LdtMt2) catalyses the formation of 3 $$\to$$ → 3 cross-links in cell wall peptidoglycan and is a target for development of antituberculosis therapeutics. Efforts to inhibit LdtMt2 have been hampered by lack of knowledge of how it binds its substrate. To address this gap, we optimised the isolation of natural disaccharide tetrapeptide monomers from the Corynebacterium jeikeium bacterial cell wall through overproduction of the peptidoglycan sacculus. The tetrapeptides were used in binding / turnover assays and biophysical studies on LdtMt2. We determined a crystal structure of wild-type LdtMt2 reacted with its natural substrate, the tetrapeptide monomer of the peptidoglycan layer. This structure shows formation of a thioester linking the catalytic cysteine and the donor substrate, reflecting an intermediate in the transpeptidase reaction; it informs on the mode of entrance of the donor substrate into the LdtMt2 active site. The results will be useful in design of LdtMt2 inhibitors, including those based on substrate binding interactions, a strategy successfully employed for other nucleophilic cysteine enzymes.

1 October 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
MMMariska de Munnik
Mariska de Munnik
KCKarina Calvopiña
Karina Calvopiña
PRPatrick Rabe
Patrick Rabe
CSChristopher J. Schofield
Christopher J. Schofield
β-lactams demonstrate promising in vitro activity against Mycobacterium species and are being explored for tuberculosis treatment; however, evidence of their in vivo efficacy versus Mycobacterium tuberculosis remains limited. To achieve broad clinically relevant potency, optimization of the classical β-lactam scaffolds or development of new or non-β-lactam inhibitors for mycobacterial transpeptidases is likely required. In mycobacteria, potential targets of β-lactams include l,d -transpeptidases (Ldts) and penicillin-binding proteins (PBPs). Reports suggest that dual inhibition of Ldts and PBPs may be necessary to achieve effective anti-mycobacterial activity, yet the specific contributions of Ldt and PBP inhibition to the β-lactam antibacterial mechanisms are poorly understood. We used fluorogenic substrate mimics to investigate the effects of β-lactams and reported Ldt Mt2 inhibitors on Mycobacterium smegmatis ( Msm ), assessing their impacts on Ldt and PBP transpeptidase activities in living cells. The results reveal a statistically significant correlation between both Ldt and PBP inhibition and Msm growth suppression; under the tested conditions, a stronger correlation between Ldt inhibition and Msm growth suppression was observed. Notably, apparent inhibition of both PBPs and Ldts was observed with all active inhibitors, though β-lactams manifest increased potency of PBP inhibition. The combination of the β-lactams meropenem and faropenem with selected Ldt Mt2 inhibitors manifested an additive inhibitory effect against Msm . Our results highlight the importance of further optimizing β-lactam efficacy versus mycobacterial PBPs and Ldt transpeptidases.

3 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
KCKarina Calvopiña
Karina Calvopiña
PRPatrick Rabe
Patrick Rabe
CSChristopher J. Schofield
Christopher J. Schofield
β-Lactams demonstrate promising in vitro activity against Mycobacterium species and are being explored for tuberculosis treatment; however, evidence of their in vivo efficacy versus Mycobacterium tuberculosis remains limited. To achieve broad clinically relevant potency, optimisation of the classical β-lactam scaffolds or development of new or non-β-lactam inhibitors for mycobacterial transpeptidases is likely required. In mycobacteria, potential targets of β-lactams include L,D-transpeptidases (Ldts) and penicillin-binding proteins (PBPs). Reports suggest that dual inhibition of Ldts and PBPs may be necessary to achieve effective anti-mycobacterial activity, yet the specific contributions of Ldt and PBP inhibition to the β-lactam antibacterial mechanisms are not understood. We used fluorogenic substrate mimics to investigate the effects of β-lactams and reported Ldt Mt2 inhibitors on Mycobacterium smegmatis ( Msm ), assessing their impacts on the transpeptidase activities of Ldts and PBPs in living cells. The results reveal a statistically significant correlation between both Ldt and PBP inhibition and Msm growth suppression; though under the tested conditions a stronger correlation between Ldt inhibition and Msm growth suppression was observed. Notably, inhibition of both PBPs and Ldts was observed in all active inhibitors, though β-lactams manifest increased potency of PBP inhibition. The combination of the β-lactams meropenem and faropenem with selected Ldt Mt2 inhibitors manifested an additive inhibitory effect against Msm . Our results highlight the importance of further optimising PBPs and Ldt transpeptidase inhibition, particularly of Ldts, to improve β-lactam efficacy versus mycobacteria.